Mirum Pharmaceuticals, Inc.
MIRM
$102.19
-$9.21-8.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5,283.63% | 75.91% | 120.41% | 76.21% | 41.94% |
| Total Depreciation and Amortization | 13.58% | 0.30% | 0.12% | 3.45% | 6.85% |
| Total Amortization of Deferred Charges | 4.85% | 4.81% | 4.48% | 4.91% | 4.59% |
| Total Other Non-Cash Items | 2,477.85% | 38.49% | 39.73% | 38.14% | 67.40% |
| Change in Net Operating Assets | 1,004.83% | -732.76% | 1,085.80% | -519.45% | -147.18% |
| Cash from Operations | -11,565.63% | 219.71% | 896.01% | 416.59% | -112.89% |
| Capital Expenditure | -1,519.51% | -2,900.00% | -3.31% | 83.83% | -215.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.24% | 142.97% | 88.57% | 91.00% | -- |
| Cash from Investing | 28.29% | 56.94% | 87.65% | 90.93% | -124,007.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,282.43% | 68.52% | 316.67% | 19.16% | 427.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,147.19% | 68.52% | 316.67% | 19.16% | 427.72% |
| Foreign Exchange rate Adjustments | -220.57% | 70.41% | 296.59% | 1,970.59% | 833.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 366.59% | 3,461.37% | 633.60% | 123.58% | -164.67% |